|
Dry Eye - A Multi-Center,
Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the
Effects of XXX Ophthalmic Solution, 2% in Subjects
with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale)-
CURRENTLY RECRUITING
Adult
VTE - A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center
Study of the Safety and Efficacy of XXX for Prophylaxis of Venous
Thromboembolism in Acutely Ill Medical Subjects During and Following
Hospitalization
- CURRENTLY RECRUITING
Adult
Heart Failure - A Phase 3
Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical
Effectiveness of XXX in Subjects With Decompensated Heart Failure -
CURRENTLY RECRUITING
Pediatric
Meningitis Vaccine - A Phase 3, Randomized, Observer-blind, Multi-Center
Study to Compare the Safety and Immunogenicity of One Dose of Novartis XXX
Vaccine with One Dose of Licensed Meningococcal ACWY Conjugate Vaccine (Menactra.)
Administered to Healthy Children 2-5 Years of Age
- COMPLETED
Major Depressive Disorder -
A Phase 2a 6-Week Randomized, Double-Blind,
Placebo-Controlled Study of XXX 80 mg q.d. and 80 mg t.i.d. in the Treatment of
Adults with Major Depressive Disorder and Concomitant Anxiety
- COMPLETED
Baby
Conjuctivitis - Phase 4 - A 7-Day, Randomized, Double-Masked, Parallel
Group, Multicenter Study To Evaluate the Safety and Efficacy of Topical XXX
0.3% Ophthalmic Solution Compared with Topical XXX 0.5% Ophthalmic Solution
for the Treatment of Presumed Bacterial Conjunctivitis in Subjects from Birth to
31 Days of Age
COMPLETED
Peadiatric Hepatitis Vaccine
- A double-blind, randomized,
multicenter study of the safety, tolerability, and immunogenicity of licenced
vaccine and modified process vaccine in healthy hepatitis B vaccine-naοve
infants.
COMPLETED
IVIG - A pilot study of Quality of
Life, Mood, Sleepiness, and Fatigue in Patients with Primary Immune Deficiency
Receiving Intravenous Immunoglobulin (IVIG)
COMPLETED
Pneumonia -
A Phase III Double-Blinded, Randomized,
Parallel Group, Multi-Center, Multi-National Comparative Study of the Safety and
Efficacy of XXX 300 mg QD to XXX 250 mg BID for the Treatment of
Community-Acquired Pneumonia in Adults COMPLETED
Pediatric
Epilepsy
- A 19-week, randomized, double-blind, multicenter, placebo-controlled safety
study to evaluate the cognitive and neuropsychological effects of XXX 20 -
60 mg/kg/day, divided in twice daily dosing, as adjunctive treatment in children
4 - 16 years old, inclusive, with partial onset seizures
COMPLETED
Pediatric
Epilepsy
- A Multi-Center,
Open-Label, Long-Term, Follow-Up Study Of The Safety And Efficacy Of XXX In
Children With Partial Onset Seizures
COMPLETED
|
